WS
OMED

Wedbush Securities’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Wedbush Securities’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,500
Closed -$40K – 927
2018
Q1 		$40K Buy
+12,500
New +$34.4K 0.01% 791

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Wedbush Securities's OMED Position: Q2 2018 in Review

Wedbush Securities sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2018, closing a stake of 12,500 shares — an estimated $40K sold.

Wedbush Securities first reported a position in OMED in Q1 2018 and held it in 1 quarter. The position peaked at $40K in Q1 2018. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2018.

  • Wedbush Securities reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Wedbush Securities sold 12,500 OncoMed Pharmaceuticals, Inc. shares in Q2 2018, an estimated $40K.
  • Wedbush Securities first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Wedbush Securities's OncoMed Pharmaceuticals, Inc. position peaked at $40K in Q1 2018.
  • 63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2018.

Based on Wedbush Securities's 13F filing for Q2 2018, filed 3 Aug 2018.